01/10/2025 | Press release | Distributed by Public on 01/10/2025 06:35
TABLE OF CONTENTS
|
|
|
|
Filed by the Registrant ☒
|
|
|
Filed by a party other than the Registrant ☐
|
|
|
|
|
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
Definitive Proxy Statement
|
☐
|
Definitive Additional Materials
|
☐
|
Soliciting Material Under §240.14a-12
|
☒
|
No fee required.
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
TABLE OF CONTENTS
1.
|
To approve a proposal to give our board of directors the authority, at its discretion, to file an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio not less than 5:1 and not greater than 16:1 (the "Reverse Stock Split"), without reducing the authorized number of shares of our common stock, with the final ratio to be selected by our board of directors in its discretion following stockholder approval, and to be effected, if at all, in the sole discretion of our board of directors at any time within one year of the date of the Special Meeting without further approval or authorization of our stockholders (the "Reverse Stock Split Proposal").
|
TABLE OF CONTENTS
|
|
|
|
|
|
By Order of the Board of Directors
|
|
|
|
||
|
|
|
|
|
|
Rajiv De Silva
Chief Executive Officer
|
|
|
|
|
|
TABLE OF CONTENTS
|
|
|
|
|
|
Page
|
|
PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS
|
|
|
1
|
INFORMATION ABOUT THE PROXY PROCESS AND VOTING
|
|
|
1
|
PROPOSAL NO. 1 APPROVAL OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT
|
|
|
5
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
|
|
13
|
ADDITIONAL INFORMATION
|
|
|
16
|
Householding of Proxy Materials
|
|
|
16
|
Incorporation by Reference
|
|
|
16
|
Other Matters
|
|
|
16
|
Exhibit A - Certificate of Amendment to Amended and Restated Certificate of Incorporation of Venus Concept Inc.
|
|
|
A-1
|
|
|
|
|
TABLE OF CONTENTS
•
|
This Proxy Statement summarizes information about the proposal to be considered at the Special Meeting and other information you may find useful in determining how to vote.
|
•
|
The Proxy Card is the means by which you actually authorize another person to vote your shares in accordance with your instructions.
|
TABLE OF CONTENTS
•
|
Proposal 1 - the approval of a proposal to give our board of directors the authority, at its discretion, to file an amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's outstanding common stock, at a ratio not less than 5:1 and not greater than 16:1, without reducing the authorized number of shares of our common stock, with the final ratio to be selected by our board of directors in its discretion following stockholder approval, and to be effected, if at all, in the sole discretion of our board of directors at any time within one year of the date of the Special Meeting without further approval or authorization of our stockholders;
|
•
|
For Proposal 1, you may either vote "For" or "Against" or abstain from voting.
|
•
|
To vote at the Special Meeting, attend the Special Meeting online and follow the instructions posted at http://www.virtualshareholdermeeting.com/VERO2025SM.
|
•
|
To vote using the Proxy Card, simply complete, sign and date the accompanying Proxy Card and return it promptly in the envelope provided. If you return your signed Proxy Card before the Special Meeting, we will vote your shares in accordance with the Proxy Card.
|
•
|
To vote by proxy over the internet, follow the instructions provided on the Proxy Card.
|
•
|
To vote by telephone, you may vote by proxy by calling the toll-free number found on the Proxy Card.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
You may submit another properly completed proxy with a later date.
|
•
|
You may send a written notice that you are revoking your proxy to our General Counsel and Corporate Secretary at 235 Yorkland Blvd., Suite 900, Toronto, Ontario M2J 4Y8.
|
•
|
You may attend the Special Meeting online and vote by following the instructions at www.proxyvote.com. Simply attending the Special Meeting will not, by itself, revoke your proxy.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
|
|
|
1:5
|
|
|
1:10
|
|
|
1:16 (4)
|
|
Common Stock Authorized (1)
|
|
|
300,000,000
|
|
|
300,000,000
|
|
|
300,000,000
|
|
|
300,000,000
|
Common Stock Issued and Outstanding
|
|
|
7,255,277
|
|
|
1,451,056
|
|
|
725,528
|
|
|
453,455
|
Number of Shares of Common Stock Reserved for Issuance (2)
|
|
|
98,276,546
|
|
|
19,655,310
|
|
|
9,827,655
|
|
|
6,142,285
|
Number of Shares of Common Stock Authorized but Unissued and Unreserved
|
|
|
194,468,177
|
|
|
278,893,634
|
|
|
289,446,817
|
|
|
293,404,260
|
Price per share, based on the closing price of our Common Stock on December 31, 2024 (3)
|
|
|
$ 0.377
|
|
|
$ 1.89
|
|
|
$ 3.77
|
|
|
$ 6.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
The Reverse Split will not have any impact on the number of shares of common stock we are authorized to issue under our Charter.
|
(2)
|
Current consists of: (i) 980,692 shares of common stock issuable upon exercise of stock options, at a weighted-average exercise price of $17.39 per share; (ii) 1,684,118 shares of common stock issuable upon exercise of warrants issued by the Company, at a weighted average price of $24.16 per share; (iii) 321,449 shares of our common stock reserved for future option and/or restricted stock unit issuance; (iv) 86,381,874 shares of our common stock issuable upon the conversion of outstanding Preferred Stock; (v) 5,508,413 shares of our common stock that are available for future issuance of Preferred Stock; (vi) 2,100,000 shares of our common stock issuable upon the conversion of convertible notes (including future accrued interest) held by EW Healthcare Partners, LP and EW Healthcare Partners-A, LP; and (vii) 1,300,000 shares of our common stock issuable upon the conversion of convertible notes (including future accrued interest) held by Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP;
|
TABLE OF CONTENTS
(3)
|
The price per share indicated reflects solely the application of the approved split ratios to the closing price of our common stock on December 31, 2024. Assumed trading price of our common stock post-Reverse Split has been rounded to two decimal places.
|
(4)
|
The Reverse Split will only be consummated at a ratio in which the Company will continue to satisfy the Nasdaq continued listing requirements.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
TABLE OF CONTENTS
•
|
each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
|
•
|
each named executive officer;
|
•
|
each of our directors; and
|
•
|
all executive officers and directors as a group.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name of Beneficial Owner
|
|
|
Common Stock
|
|
|
Securities
Exercisable
within
60 days
|
|
|
Amount and
Nature of
Beneficial
Ownership
|
|
|
Percent of
Class
|
5% or Greater Stockholder (other than directors and executive officers)
|
|
|
|
|
|
|
|
|
||||
EW Healthcare Partners, L.P. and related investment entities (1)
|
|
|
5,280,050
|
|
|
-
|
|
|
5,280,050
|
|
|
46.13%
|
Madryn Asset Management and related investment entities (2)
|
|
|
1,450,330
|
|
|
-
|
|
|
1,450,330
|
|
|
16.88%
|
Saudi Economic and Development Securities Company and related investment entities (3)
|
|
|
386,570
|
|
|
-
|
|
|
386,570
|
|
|
5.25%
|
HealthQuest Partners II, L.P. and related investment entities (4)
|
|
|
744,106
|
|
|
-
|
|
|
744,106
|
|
|
9.86%
|
Named Executive Officers, Executive Officers and Directors:
|
|
|
|
|
|
|
|
|
||||
Rajiv De Silva (5)
|
|
|
193,337
|
|
|
13,750
|
|
|
207,087
|
|
|
2.81%
|
Domenic Della Penna (6)
|
|
|
58,325
|
|
|
1,042
|
|
|
59,367
|
|
|
*
|
Ross Portaro (7)
|
|
|
37,523
|
|
|
1,530
|
|
|
39,053
|
|
|
*
|
Hemanth Varghese (8)
|
|
|
53,334
|
|
|
4,583
|
|
|
57,917
|
|
|
*
|
Anna Georgiadis (9)
|
|
|
25,673
|
|
|
522
|
|
|
26,195
|
|
|
*
|
Michael Mandarello (10)
|
|
|
21,944
|
|
|
668
|
|
|
22,612
|
|
|
*
|
William McGrail (11)
|
|
|
11,004
|
|
|
473
|
|
|
11,477
|
|
|
*
|
Scott Barry (1)(12)
|
|
|
5,280,050
|
|
|
-
|
|
|
5,280,050
|
|
|
46.13%
|
Louise Lacchin (13)
|
|
|
8,680
|
|
|
-
|
|
|
8,680
|
|
|
*
|
Fritz LaPorte (14)
|
|
|
10,090
|
|
|
105
|
|
|
10,195
|
|
|
*
|
Tony Natale (15)
|
|
|
9,129
|
|
|
105
|
|
|
9,234
|
|
|
*
|
Keith Sullivan (16)
|
|
|
14,963
|
|
|
-
|
|
|
14,963
|
|
|
*
|
Stanley Tyler Hollmig (17)
|
|
|
22,668
|
|
|
70
|
|
|
22,738
|
|
|
*
|
Directors and officers as a group (13 Individuals)
|
|
|
5,746,720
|
|
|
22,848
|
|
|
5,769,568
|
|
|
48.96%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
Less than 1.0%.
|
(1)
|
Represents (i) 1,047,065 shares of common stock and 1,835,065 preferred shares (convertible to 2,009,599 shares of common stock) held by EW Healthcare Partners, L.P., or EWHP, (ii) 42,126 shares of common stock and 73,830 preferred shares (convertible to 80,854 shares of common stock) held by EW Healthcare Partners-A, L.P., or EWHP-A, (iii) 1,752,195 shares of common stock issuable upon conversion
|
TABLE OF CONTENTS
(2)
|
Represents (i) 41,455 shares of common stock held by Madryn Health Partners, LP, referred to herein as "MHP" (ii) 4,438 shares of common stock issuable upon the exercise of warrants held by MHP, (iii) 490,726 shares of common stock issuable upon the exercise of Series X preferred stock by MHP, (iv) 70,586 shares of common stock held by Madryn Health Partners (Cayman Master), LP, referred to herein as "MHP-C," (v) 7,558 shares of common stock issuable upon the exercise of warrants held by MHP-C, and (vi) 835,567 shares of common stock issuable upon the exercise of Series X preferred stock by MHP-C, The shares of common stock shown to be beneficially owned excludes (a) 582,034 shares of common stock issuable upon conversion of Series X preferred stock and 28,881,100 shares of common stock issuable upon conversion of Series Y preferred stock held by MHP, (b) 417,810 shares of common stock issuable upon conversion of convertible notes held by MHP, (c) 991,033 shares of common stock issuable upon conversion of Series X preferred stock and 49,175,800 shares of common stock issuable upon conversion of Series Y preferred stock held by MHP-C, and (d) 711,406 shares of common stock issuable upon conversion of convertible notes held by MHP-C, as such conversions cannot occur within 60 days after December 31, 2024 due to limitations on convertibility imposed by the rules and regulations of the Nasdaq Capital Market. Each of MHP and MHP-C have sole voting and investment power with respect to such respective shares of common stock. Madryn Health Advisors, LP, referred to herein as "MHA" the general partner of MHP and MHP-C, may also be deemed to have sole voting and investment power with respect to such shares of common stock. Madryn Asset Management, L.P., referred to herein as "MAM", the investment advisor of MHP and MHP-C, may also be deemed to have sole voting and investment power with respect to such shares of common stock. The principal address of MHP, MHP-C, MHA, MAM and each of the above-referenced individuals is c/o Madryn Asset Management, L.P., 330 Madison Avenue - Floor 33, New York, NY 10017.
|
(3)
|
Represents (i) 116,285 shares of common stock held by SC Venus Opportunities Limited, (ii) 103,083 shares of common stock held by SC Venus US Limited, (iii) 54,202 shares of common stock and warrants that may be exercised for 33,000 shares of common stock held by SEDCO Capital Cayman Limited, and (iv) warrants that may be exercised for 80,000 shares of common stock held by SEDCO Capital Global Funds-SC Private Equity Global Fund IV. Saudi Economic and Development Securities Company is the investment manager of SC Venus US Limited, SC Venus Opportunities Limited and SEDCO Capital Global Funds-SC Private Equity Global Fund IV and may be deemed to beneficially own securities held by SC Venus US Limited or SC Venus Opportunities Limited or SEDCO Capital Global Funds-SC Private Equity Global Fund IV. Saudi Economic and Development Securities Company is the parent of SEDCO Capital Cayman Limited and may be deemed to beneficially own securities held by SEDCO Capital Cayman Limited. The principal address of SEDCO Capital Cayman Limited is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The principal address of SC Venus US Limited and SC Venus Opportunities Limited is PO Box 709, Willow House, Cricket Square, Grand Cayman E9 KY1-1107. The principal address of SEDCO Capital Global Funds - SC Private Equity Global Fund IV is 5 Rue Jean Monnet, Luxembourg N4 L-2180.
|
(4)
|
Represents 453,043 shares of common stock and 335,000 preferred shares (convertible to 223,345 shares of common stock) held by HealthQuest. HealthQuest Venture Management II, L.L.C., or HealthQuest Management, is the general partner of HealthQuest and HealthQuest Management may be deemed to have voting and dispositive power over the shares held by HealthQuest. Garheng Kong was a member of the Company's board of directors until his resignation on December 2, 2024. Dr. Kong is the managing member of HealthQuest Management and as such, may be deemed to exercise shared voting and investment power with respect to such shares. Dr. Kong is also the Managing Partner and controlling member of HealthQuest Capital Management Company, LLC, the general partner of HealthQuest Capital Management, L.P., or HQCM, and may be deemed to have sole voting and dispositive power with respect to the options held of record by HQCM. Dr. Kong disclaims beneficial ownership of such shares of common stock except to the extent of his pecuniary interest therein. Also includes 60,000 shares issuable upon exercise of warrants which were exercisable beginning September 16, 2020. As of December 31, 2024, 7,718 stock options were fully vested and no stock options that will vest within 60 days of December 31, 2024. The address for HealthQuest is 1301 Shoreway Road, Suite 350, Belmont California 94002.
|
(5)
|
Represents 83,334 shares of common stock and 110,003 stock options which were fully vested and 13,750 stock options which will vest within 60 days of December 31, 2024.
|
(6)
|
Represents 10,093 shares, and 48,232 stock options which were fully vested and 1,042 stock options which will vest within 60 days of December 31, 2024.
|
(7)
|
Represents 8,932 shares, and 28,591 stock options which were fully vested and 1,530 stock options which will vest within 60 days of December 31, 2024.
|
(8)
|
Represents 16,667 shares of common stock and 36,667 stock options which were fully vested and 4,583 stock options which will vest within 60 days of December 31, 2024.
|
(9)
|
Represents 1,712 shares of common stock, 23,961 stock options that were fully vested and 522 stock options that will vest within 60 days of December 31, 2024.
|
(10)
|
Represents 1,491 shares of common stock, 20,453 stock options that were fully vested and 668 stock options that will vest within 60 days of December 31, 2024
|
(11)
|
Represents 519 shares of common stock, 10,485 stock options that were fully vested and 473 stock options that will vest within 60 days of December 31, 2024.
|
TABLE OF CONTENTS
(12)
|
As of December 31, 2024, 7,718 stock options were fully vested and no stock options that will vest within 60 days of December 31, 2024. Also includes 270,000 shares issuable upon the exercise of warrants which were exercisable beginning September 16, 2020.
|
(13)
|
As of December 31, 2024, 8,680 stock options were fully vested and no additional stock options that will vest within 60 days of December 31, 2024.
|
(14)
|
As of December 31, 2024, 10,090 stock options were fully vested and 105 additional stock options will vest within 60 days of December 31, 2024.
|
(15)
|
Represents 9,129 stock options which were fully vested as of December 31, 2024. 105 additional stock options will vest within 60 days of December 31, 2024.
|
(16)
|
Represents 8,277 shares and 6,686 stock options which were fully vested and no additional stock options that will vest within 60 days of December 31, 2024.
|
(17)
|
Represents 19,334 shares and 3,334 stock options which were fully vested and 70 additional stock options which will vest within 60 days of December 31, 2024.
|
TABLE OF CONTENTS
|
|
|
|
|
|
By Order of the Board of Directors
|
|
|
|
||
|
|
|
|
|
|
Rajiv De Silva
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
TABLE OF CONTENTS
1.
|
Article IV of the Certificate of Incorporation of the Corporation, as presently in effect, is hereby amended by deleting Section 3 in its entirety and replacing it with the following Section 3:
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
||
|
|
|
|
Authorized Officer
|
||
|
|
|
|
|||
|
|
Title:
|
|
|
||
|
|
Name:
|
|
|
||
|
|
|
|
Print or Type
|
TABLE OF CONTENTS
TABLE OF CONTENTS